The Canadian securities ecosystem recently received a consolidated schedule of upcoming shareholder meetings for reporting issuers, provided through CDS Clearing and Depository Services Inc. This compilation lists company record dates, meeting dates and meeting types, allowing investors and advisors to plan proxy voting, attendance and engagement. The release is routine but important: it centralizes information that can otherwise be scattered across individual press releases and filings.
Below we present a curated snapshot of the schedule and explain how to read the codes and symbols used in the release.
Several notable names appear on the list, and we also call out two separate investor-facing events: Gain Therapeutics at the 38th Annual ROTH Conference and Genprex at BIO Europe Spring — events that offer management access beyond routine shareholder meetings.
Table of Contents:
Snapshot of notable meeting entries
The CDS-provided calendar covers a wide range of issuers, from miners to REITs and biotech companies. Examples from the list include: Aecon Group Inc. with a record date of April 9, 2026 and a meeting on June 1, 2026 (type: AG); B2Gold Corp. (record date April 13, 2026; meeting June 4, 2026; type: AGS); and Ballard Power Systems Inc. (record date April 6, 2026; meeting June 3, 2026; type: A). Other entries include Black Pearl Resources Corp. (record date March 18, 2026; meeting April 9, 2026; type: S) and CATHEDRA BITCOIN INC. (record date March 25, 2026; meeting May 15, 2026; type: S).
The calendar also lists numerous other issuers: for example, Dream Industrial REIT, Dream Office REIT, and Dream Unlimited Corp. all show record dates of April 10, 2026 with meetings in early June 2026. Energy and resources names such as Northland Power Inc. (record April 6, 2026; meeting May 20, 2026) and Seabridge Gold Inc. (record March 30, 2026; meeting May 22, 2026) are included as well. This breadth reflects the seasonal cadence of corporate annual general meetings in Canada.
Understanding codes, symbols and practical implications
The published table uses compact codes to convey meeting type and status: common meeting types include A for annual meeting and S for special meeting. The release also flags changes and cancellations: an asterisk (*) denotes a change in previously reported information, while a percent sign (%) indicates a cancelled meeting. An at symbol (@) would mark an adjourned meeting if present. These markers help stakeholders identify updates without parsing every issuer filing.
Legend and definitions
The release clarifies shorthand for uncommon meeting types as well: G stands for general meeting, B for bondholder meeting, and C for court meeting. Knowing these distinctions is useful because an annual meeting typically covers director elections and auditor ratification, whereas a special meeting often relates to a discrete transaction or extraordinary corporate matter.
Investor actions and timing
Investors should note two calendar anchors: the record date (the cutoff to be eligible to vote or receive notices) and the actual meeting date. If you plan to attend or submit proxies, confirm both dates and follow the issuer’s instructions for registration or remote participation. The CDS list is a starting point; you should still consult the issuer’s formal meeting circular or SEDAR/SEDAR+ filing for agenda details and proxy materials.
Featured investor events: Gain Therapeutics and Genprex
Alongside routine shareholder meetings, investor conferences and corporate roadshows offer additional opportunities for engagement. Gain Therapeutics, Inc. announced that Gene Mack, President and CEO, will take part in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference, held March 22-24, 2026 in Dana Point, CA. The fireside chat is scheduled for Monday, March 23, 2026 at 11:30 a.m. PT and will be available via live webcast or replay on the company’s investor relations page. Interested parties were invited to arrange one-on-one meetings via their ROTH representative or by contacting the company directly.
Genprex, Inc. announced its delegation will attend BIO Europe Spring, taking place March 23-25, 2026 in Lisbon, Portugal. The company’s participation was described in a press release dated March 10, 2026. Attendance at international partnership forums such as BIO Europe provides management teams a venue to discuss collaborations, licensing and clinical programs outside of formal shareholder meeting settings.
Where to find the original schedule and next steps
The calendar is compiled from issuer-supplied data via CDS Clearing and Depository Services Inc. For complete line-by-line listings, investors and advisors can consult the CDS website. Additionally, many issuers publish the same meeting specifics through press releases or regulatory filings; cross-referencing those sources ensures you have the full agenda, proxy materials and voting instructions before each meeting. Staying proactive about these dates helps preserve voting rights and supports informed shareholder engagement.
